Neurocrine Biosciences | Brutto Fortjeneste På Salg



Gross Profit On Sales Endring Dato
AbbVie USD 10.71B 458M 2024-12
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
ALKERMES USD 257.31M 110.81M 2025-03
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Amgen USD 5.54B 430M 2025-03
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Cytokinetics -160545000 81.19M 2024-09
Dynavax Technologies USD 58.62M 8.92M 2024-12
Exelixis USD 546.79M 24.58M 2025-01
Gilead Sciences USD 5.99B 17M 2024-12
Halozyme Therapeutics USD 216.46M 39.49M 2025-03
Incyte USD 985.09M 111.22M 2025-03
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Pfizer USD 11.12B 987M 2025-03
Prothena -59001000 66.45M 2024-09
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Repligen USD 90.76M 10.44M 2025-03
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
Teva Pharmaceutical Industries USD 2.12B 85M 2024-12
Ultragenyx Pharmaceutical USD 110.63M 37.35M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Neurocrine Biosciences Brutto Fortjeneste På Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.